| Literature DB >> 32438566 |
Morgane Frapin1, Simon Guignard1, Dimitri Meistermann2, Isabelle Grit1, Valentine S Moullé1, Vincent Paillé1, Patricia Parnet1, Valérie Amarger1.
Abstract
Fetal brain development is closely dependent on maternal nutrition and metabolic status. Maternal protein restriction (PR) is known to be associated with alterations in the structure and function of the hypothalamus, leading to impaired control of energy homeostasis and food intake. The objective of this study was to identify the cellular and molecular systems underlying these effects during fetal development. We combined a global transcriptomic analysis on the fetal hypothalamus from a rat model of maternal PR with in vitro neurosphere culture and cellular analyses. Several genes encoding proteins from the mitochondrial respiratory chain complexes were overexpressed in the PR group and mitochondrial metabolic activity in the fetal hypothalamus was altered. The level of the N6-methyladenosine epitranscriptomic mark was reduced in the PR fetuses, and the expression of several genes involved in the writing/erasing/reading of this mark was indeed altered, as well as genes encoding several RNA-binding proteins. Additionally, we observed a higher number of neuronal-committed progenitors at embryonic day 17 (E17) in the PR fetuses. Together, these data strongly suggest a metabolic adaptation to the amino acid shortage, combined with the post-transcriptional control of protein expression, which might reflect alterations in the control of the timing of neuronal progenitor differentiation.Entities:
Keywords: differentiation; epitranscriptomics; fetal brain; hypothalamus; maternal nutrition; mitochondria; neurogenesis; protein restriction; transcriptomics
Mesh:
Year: 2020 PMID: 32438566 PMCID: PMC7284977 DOI: 10.3390/nu12051464
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Litter and fetus characteristics at embryonic day 17 (E17).
| Controls | Protein Restricted | ||||
|---|---|---|---|---|---|
| Litter Size | 13.00 ± 3.39 ( | 14.13 ± 2.61 ( | 0.50 * | ||
| Maternal Weight Gain (g) | 112.39 ± 17.77 ( | 99.47 ± 21.12 ( | 0.16 * | ||
| Fetal Weight (g) | ♀ ( | ♂ ( | ♀ ( | ♂ ( | Group: 0.41 # |
| 0.76 ± 0.05 | 0.79 ± 0.05 | 0.77 ± 0.07 | 0.81 ± 0.06 | Sex: <0.0001 # | |
| Placenta Weight (g) | 0.39 ± 0.06 ( | 0.40 ± 0.07 ( | 0.85 * | ||
| PFR (Placenta–Fetus Ratio) | 0.51 ± 0.09 ( | 0.52 ± 0.10 ( | 0.83 * | ||
* Mann–Whitney test; # two-way ANOVA test.
Figure 1Total number of cells obtained from each E17 fetal hypothalamus after mechanical dissociation. The cells were counted on a hemocytometer (PR: n = 27 males and 42 females C: n = 32 males and 28 females). (two-way ANOVA: group effect * p = 0.04, sex effect p = 0.35) (boxplot: median, first and third quartiles).
Figure 2Neural cell type proportions in total hypothalamic cells sampled at E17 and after three days in vitro (3 DIV) labelled by immunocytochemistry and automatically counted on microscopy images. Each marker is illustrated by images obtained by optical microscopy (scale bars, 20 µm). Red and orange labelling is for markers of interest, Ki67 (A), Nestin (B), TUJ1 = TUBB3 (C) and MAP2 (D) and nucleus are labelled with DAPI in blue (n = 6–13 per group). Group and sex effects were tested using two-way ANOVA, * group effect p = 0.02. Non-significant p values are not mentioned. (boxplot: median, first and third quartiles).
Figure 3Volcano plot (A) and MA plot (B) of differentially expressed genes at E17 in the protein restriction (PR) group compared to Control group (PR: n = eight males + eight females, C: n = eight males + eight females). (padj = adjusted p-value from Deseq2 analysis). Mean expression corresponds to the average normalized read number.
Top 20 upregulated genes in the protein-restricted group.
| Gene Symbol | Log2FC | Padj | Base Mean | Full Name | Function(s) * |
|---|---|---|---|---|---|
|
| 0.469 | 0.031 | 24.122 | Solute carrier family 35 member C2 | May play a role in cellular response to tissue hypoxia |
|
| 0.463 | 0.042 | 12.650 | Phosphopantothenoylcysteine synthetase | Involved in the biosynthesis of coenzyme A, a precursor of Acetyl CoA |
|
| 0.452 | 0.001 | 817.685 | Cold shock domain containing E1 | RNA-binding protein—prevents neuronal differentiation in neural stem cells |
|
| 0.437 | 0.028 | 19.597 | Nipa magnesium transporter 2 | Non-imprinted gene in Prader–Willi/Angelman syndrome region |
|
| 0.429 | 0.006 | 117.035 | Cytochrome C oxydase assembly factor 5 | Involved in the mitochondrial complex IV assembly |
|
| 0.428 | 0.002 | 250.612 | Cold inducible RNA-binding protein | Essential for embryonic gastrulation and neural development |
|
| 0.423 | 0.030 | 91.038 | Heparan-sulfate 6-O-sulfotransferase 1 | Critical for normal neuronal development, may play a role in neuron branching |
| LOC100174910 | 0.418 | 0.010 | 48.852 | Glutaredoxin-like protein | Involved in oxidation-reduction process. May be involved in cell redox homeostasis |
|
| 0.407 | 0.044 | 34.218 | WD repeat domain-containing protein 83 | Involved in response to hypoxia |
|
| 0.406 | 0.025 | 27.565 | Transmembrane protein 53 | |
|
| 0.405 | 0.002 | 83.937 | Ubiquitin conjugating enzyme E2N | Involved in protein ubiquitination. Plays a role in the control of cell cycle and differentiation |
|
| 0.397 | 0.044 | 55.090 | Transmembrane and coiled-coil domains protein 2 | Expressed in endoplasmic reticulum |
|
| 0.395 | 0.044 | 23.013 | COPII coat complex component | Involved in protein transport from endoplasmic reticulum |
|
| 0.393 | 0.001 | 120.626 | coenzyme Q7 hydroxylase | Involved in ubiquinone synthesis, in mitochondrial respiratory metabolism |
|
| 0.391 | 0.006 | 66.458 | Chromatin accessibility complex protein 1 | Histone-fold protein that binds DNA. May be involved in cell growth and survival |
|
| 0.377 | 0.044 | 20.552 | RNA-binding protein 7 | Member of the exosome targeting complex, involved in RNA degradation |
|
| 0.373 | 0.031 | 87.528 | WT1 associated protein | Member of the complex that mediate m6A methylation of RNAs |
|
| 0.367 | 0.032 | 30.933 | Mitochondrial transcription termination factor 1 | DNA-binding protein, involved in termination of mitochondrial transcription |
|
| 0.365 | 0.026 | 1055.600 | Myristoylated alanine rich protein kinase C substrate | Binds protein of cytoskeleton, may be involved in cell migration |
|
| 0.365 | 0.044 | 39.620 | Solute carrier family 66 member 2 | Involved in phospholipid translocation |
*: from the UNIPROT database (www.uniprot.org) [72] and the NCBI/Gene database (www.ncbi.nlm.nih.gov/gene) [73].
Top 20 downregulated genes in the protein-restricted group.
| Gene Symbol | log2FC | Padj | Base Mean | Full Name | Function(s) * |
|---|---|---|---|---|---|
|
| −0.807 | 0.010 | 13.066 | Serine Threonine protein kinase | Role in polarization of neurons and centrosome duplication |
|
| −0.676 | 0.002 | 19.199 | FGFR1 oncogen partner | Required for anchoring microtubules to the centrosomes. Involved in cell proliferation |
|
| −0.658 | 0.003 | 22.941 | Quaking | RNA-binding protein that regulates pre-mRNA splicing, export, stability and translation. Involved in oligodendrogenesis |
|
| −0.636 | 0.024 | 19.373 | Transcription factor 20 | Transcriptional activator. May be involved in neurodevelopment |
|
| −0.625 | 0.013 | 23.749 | Calcium/calmodulin dependent serine protein kinase | Involved in synaptic membrane protein anchoring. Contributes to neurodevelopment |
|
| −0.607 | 0.021 | 12.515 | Epidermal growth factor receptor pathway substrate 15 | Involved in cell growth regulation. May be involved in the control of cell proliferation |
|
| −0.600 | 0.009 | 56.779 | Roundabout guidance receptor 1 | Involved in axon guidance and neuronal precursor cell migration |
|
| −0.569 | 0.010 | 19.145 | Also known as Tcrp1 | Involved in cancer chemotherapy resistance |
|
| −0.566 | 0.009 | 18.290 | IQ motif containing GTPase activating protein 1 | Regulates the assembly and dynamic if the cytoskeleton. May promote neurite outgrowth. |
|
| −0.560 | 0.025 | 15.498 | Phosphatase and actin regulator 3 | Associated with the nuclear scaffold in proliferating cells |
|
| −0.548 | 0.009 | 28.595 | Myosin 18A | Associated with the Golgi. May be required for cell migration |
|
| −0.541 | 0.045 | 17.734 | Sestrin 3 | Required for regulation of glucose and insulin regulation. May be involved in the protection againt oxidative stress |
|
| −0.530 | 0.044 | 16.245 | Potassium calcium-activated channel subfamily M alpha 1 | Involved in the control of neuron excitability |
|
| −0.529 | 0.002 | 95.164 | Piccolo presynaptic cytomatrix protein | Involved in synaptogenesis |
|
| −0.526 | 0.024 | 19.383 | beta−1,4-mannosyl-glycoprotein 4 beta-N-Acetylglucosaminyltransferase | May be involved in response to oxidative stress in brain and in cell migration regulation |
|
| −0.526 | 0.049 | 10.279 | TIMP metallopeptidase inhibitor 3 | |
|
| −0.518 | 0.007 | 43.989 | Serine Threonine protein kinase TAO1 | Acts as a regulator of cytoskeleton stability. May be involved in the induction of apoptosis |
|
| −0.515 | 0.031 | 15.813 | Neuroligin 1 | Neuronal cell surface protein. May be involved in the formation and remodeling of synapses |
|
| −0.511 | 0.025 | 18.776 | Karyopherin subunit beta 1 | Involved in nuclear protein import, including ribosomal proteins and histone H1 |
|
| −0.510 | 0.028 | 14.084 | Sarcolemma associated protein | Membrane associated protein |
*: from the UNIPROT database (www.uniprot.org) [72] and the NCBI/Gene database (www.ncbi.nlm.nih.gov/gene) [73].
Figure 4Selection of the gene families and metabolic pathways significantly enriched in differentially expressed genes (Fast Gene Set Enrichment Analysis (FGSEA), padj < 0.05). The pathways with a Normalized Enrichment Score (NES) > 0 are enriched in genes upregulated in the PR group and pathways with an NES < 0 are enriched in genes downregulated in the PR group.
Figure 5Mitochondrial membrane potential, DNA and protein quantification from total E17 fetal hypothalamus. (A) Mitochondrial membrane potential was quantified in dissociated total fetal hypothalamus cells by MitoTracker Red CMXRos and expressed in Relative Fluorescence Units (RFU)/lived cells x 1000 (C: n = two males + four females, PR: n = two males + nine females) (two-way ANOVA: group effect * p = 0.04, sex effect p = 0.91). (B) Mitochondrial DNA was quantified using qPCR amplification on total DNA from E17 whole hypothalamus of the mitochondrial CytB gene and normalized with two nuclear genes Gapdh and Zfx-Zfy. (C,D) Four proteins from the mitochondrial respiratory chain complexes (SDHB, MTCO1, UQCRC2 and ATP5A from Complexes II, III, IV and V, respectively) were quantified using Western blot on total proteins from E17 total hypothalamus in four males (C) and four females (D) from each group. Total protein stain was used for normalization. (Mann Whitney * p < 0.05) (p: Positive control = mitochondrial protein extract from rat heart tissue lysate (Abcam ab110341)) (boxplot: median, first and third quartiles).
Figure 6Quantification of the CSDE1 protein in E17 fetal Hypothalamus using Western blot. (PR: n = four males + four females, C: n = four males + four females) (ANOVA, group effect * p = 0.04, sex-effet p = 0.18) (boxplot: median, first and third quartiles).
Figure 7(A) Normalized expression level of the genes from the m6A epitranscriptomic machinery obtained using DESeq2 on E17 Hypothalamic RNA sequenced in DGE-seq (PR: n = eight males + eight females, C: n = eight males + eight females) (adjusted p-value from Deseq2 analysis: * padj < 0.05). (B) Quantification of the percentage of m6A in total RNA from E17 fetal hypothalamus using m6A immunodetection assay (PR: n = 10 males + nine females, C: n = 10 males + seven females) (two-way ANOVA group effect p = 0.05, sex effect p = 0.73) (boxplot: median, first and third quartiles).